Refine by
Cell Isolation Articles & Analysis
27 news found
Although cancer originates from mutations accumulating within cancer cells, disease progression and treatment response are both strongly regulated by non-mutated cells within the tumour microenvironment. Significant advances have been made in recent years in the study of cancer-associated fibroblasts (CAFs). These cells regulate cancer metastasis ...
In the fourth and final application note of our “Mastering Tissue Dissociation” series, we focused on spleen tissue dissociation to isolate single cells. Using spleen samples from mice housed in standard conditions (UAR BioMedTech Facilities), we achieved a cell viability rate of 87.12%. This method preserves ...
Obtaining viable single cells from lung tissue is essential for understanding respiratory function and disease mechanisms. Despite its importance, isolating these cells remains challenging. Bertin Technologies’ Precellys Multi Tissue Dissociation kit, in conjunction with the Precellys Evolution Touch (or Precellys Evolution), offers an ...
Introduction We recently sat down with one of our valued customers, Dr Alexis Rossignol (Clean Cells), to discuss his experience with VIPS PRO, our cutting-edge technology designed to streamline and enhance the early stages of cell line development. This interview provides insight into Clean Cells’ quest to automate and increase single-cell seeding while having undisputable proof ...
Liquid biopsy testing offers a complementary alternative to solid tumor testing, which is not always feasible due to insufficient tissue, low quality tissue, or the invasiveness of the procedure. The testing works by isolating cell-free DNA (cfDNA) from blood plasma to uncover circulating tumor DNA (ctDNA). Isolating these DNA samples from a ...
Liquid biopsy testing offers an alternative to solid tumor testing by isolating cell-free DNA (cfDNA) from blood plasma, which may uncover circulating tumor DNA (ctDNA). ...
IRVINE, Calif. – AUG. 29, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, today announced the publication of safety and efficacy results from Phase 1 and Phase 2 clinical trials investigating its anti-SARS-CoV-2 vaccine candidate AV-COVID-19 that is made at point-of-care by third-party personnel. The results were published in the article ...
Nodexus was selected for an SBIR grant for the development of a novel cancer stem cell detection and isolation platform leveraging the core Nodexus technology ...
About RepliCel Life Sciences RepliCel is a regenerative medicine company focused on developing cell therapies for aesthetic and orthopedic conditions affecting what the Company believes is approximately one in three people in industrialized nations, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. These conditions, often associated with aging, ...
TX200 is composed of autologous Treg cells engineered to express an HLA-A2 CAR. This investigational cell therapy is being assessed in HLA-A2 negative patients receiving a mismatched HLA-A2 positive kidney from a living donor. TX200 cells are expected to localize to the graft and activate upon binding to the HLA-A2 antigen. ...
About RepliCel Life Sciences RepliCel is a regenerative medicine company focused on developing cell therapies for aesthetic and orthopedic conditions affecting what the Company believes is approximately one in three people in industrialized nations, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. These conditions, often associated with aging, ...
The publication provides an approachable overview of stem cell biology and clarifies common misconceptions about adipose-derived regenerative cells (ADRCs) including vascular-associated pluripotent stem cells (vaPS cells). ...
” With respect to the newly granted and allowed patents, RepliCel has been issued a key patent in Japan related to the Company's RCT-01 cell therapy for the treatment of chronic tendinopathy and two patents, one in Brazil and another in Mexico, relating to its RCS-01 regenerative cell therapy for skin rejuvenation. ...
The dispute between Shiseido and RepliCel is related to a license for Asia to RepliCel’s cell therapy technology for androgenetic alopecia, which is the leading cause of male and female pattern hair loss. ...
About RepliCel Life Sciences RepliCel is a regenerative medicine company focused on developing cell therapies for aesthetic and orthopedic conditions affecting what the Company believes is approximately one in three people in industrialized nations, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. These conditions, often associated with aging, ...
Pluripotent stem cells have the ability to become any cell type of the adult body. The newly-released publication, entitled “Perspective: Why and How Ubiquitously Distributed, Vascular-Associated, Pluripotent Stem Cells in the Adult Body (vaPS Cells) Are the Next Generation of Medicine“, has been published in the ...
Thermo Fisher Scientific today announced the launch of Gibco Cell Therapy Systems (CTS) NK-Xpander Medium, a GMP-manufactured cell culture medium that supports large-scale growth and culture of functional natural killer (NK) cells with or without the use of feeder cells. ...
The CTS Dynabeads platform is part of Thermo Fisher's proven Cell Therapy Systems (CTS) product portfolio designed to ease the transition from clinical development to commercial manufacturing of T-cell therapies. The CTS product line is a comprehensive portfolio of products designed to work together, from cell ...
In contrast to autologous cell therapies, which are produced using a patient's own cells, allogeneic cell therapies are derived from healthy donor tissue, potentially enabling more scalable, cost-effective cell therapy manufacturing. ...
InGeneron, Inc., a regenerative medicine and cell therapy company, today announced the publication of promising results in developing a novel treatment for chronic ischemic heart failure using its regenerative cell therapy platform. ...